Boswellia serrata for Asthma

Verdict: Weak, outdated evidence for asthma

Boswellia serrata is not an established treatment for asthma. A few small, dated trials hint at possible breathing benefits, but the evidence is too weak and unreplicated to rely on, and it should never replace prescribed inhalers or controller medication.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Weak (Grade C) rating because the entire human evidence base is just three small, low-quality randomized trials and no meta-analysis exists. The largest, Gupta 1998 (PMID 9810030, n=80), reported that 70% of the Boswellia group improved versus 27% on placebo, but it had a documented baseline imbalance (the treatment arm started with more severe asthma), reported no p-value, scored only 3/5 on the Jadad scale, and has never been independently replicated in nearly three decades.

The two newer trials do not strengthen the case. A 2015 open-label, industry-context study of a Boswellia phytosome (Casperome) in 32 patients (PMID 26502867) suggested fewer rescue inhalations, but its design is highly prone to bias. A 2018 double-blind trial (PMID 29210124, n=36) showed real symptom and cytokine improvements, yet it tested Boswellia combined with Aegle marmelos, so any benefit cannot be attributed to Boswellia alone.

Authorities reinforce the caution. The FDA treats Boswellia only as a flavoring agent and has issued warning letters against therapeutic claims; the EU/EFSA rejected its health claims and authorizes no human use; and major clinics (Mayo, Cleveland, Harvard) and asthma guidelines (GINA, ATS) are silent on it. The WHO monograph lists asthma as a traditional use 'supported by clinical data,' but that is a low, traditional-medicine bar, not modern proof.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.53
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
62%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.53
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind,
PMID: 9810030 1998 RCT (double-blind) n = 80
Finding: 70% of Boswellia group showed symptom/lung-function improvement vs 27% placebo; p-value not reported in abstract. Systematic review (Ernst 2008, PMC2605614) noted Jadad score 3/5 and baseline imbalance (treatment arm had more severe asthma).
🟠 Limited quality
View on PubMed
Functional study on Boswellia phytosome as complementary intervention in asthmatic patients
PMID: 26502867 2015 RCT (open-label) n = 32
Finding: Add-on Casperome reduced required rescue inhalations vs control; no p-value reported in abstract; multicenter but small and open-label.
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
A novel herbal composition containing extracts of Boswellia serrata gum resin and Aegle marmelos fruit
PMID: 29210124 2018 RCT (double-blind) n = 36
Finding: Significant symptom improvement by day 14 (p=0.0002); IFN-γ increased (p=0.0014) and IL-4 decreased (p=0.0497) at 56 days vs placebo. Confounded by multi-herb formula — Boswellia effect not isolable.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FLAVORING AGENT OR ADJUVANT source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
易誤用中藥材 乳香(Olibanum)— 乳香為橄欖科植物卡氏乳香樹(Boswellia carterii Birdw.)及同屬數種植物皮部滲出的油膠樹脂。列入食藥署「誤用中藥材目錄」第55項(公告日期2010-01-05)。 source↗
L4e WHO
Supportive
Gummi Boswellii (the gum-resin from Boswellia species) is included in WHO Monographs on Selected Medicinal Plants, Volume 4 (2009), pages 48–60, covering uses supported by clinical data, uses described in pharmacopoeias and traditional systems of medicine, and uses described in folk medicine. source↗
L5a NIH Office of Dietary Supplements
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-asthma-INT-boswellia-001 繁體中文版 →